Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANTICOV-EPI household transmission ancillary study
PACTR202010718451278Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of acetaminophen, hydroxychloroquine and lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Drugs for Neglected Diseases initiative. Started Nov 2020; status: completed.
02
Drugs
acetaminophenhydroxychloroquinelopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202010718451278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202010718451278.